Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 15Neoplasm Metastasis 3Hereditary Sensory and Autonomic Neuropathies 3Squamous Cell Carcinoma of Head and Neck 2Hyperglycemia 2Advanced Breast Cancer 2Vascular Malformations 1Triple Negative Breast Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Exanthema 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Arteriovenous Malformations 1Anatomic Stage III Breast Cancer AJCC v8 1Adenocarcinoma of Lung 1

Interventions

Fulvestrant 2ruxolitinib 1ceterizine hydrochloride 1capivasertib 1benralizumab 1Triamcinolone Acetonide 1Tetracycline 1Sirolimus 1Prednisone 1Panitumumab 1Minocycline 1Loperamide 1Irinotecan 1IFL protocol 1Hydrocortisone 1Gels 1Erlotinib Hydrochloride 1Doxycycline 1Dapsone 1Clindamycin 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Exanthema × Alpelisib × Clear all
NCT05966584 2024-08-29

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
Breast

Breast Neoplasms, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡